EICHORCondition: Cancer · Sponsor: Resilience
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The goal of this clinical trial is to learn if Resilience PRO, a digital solution performing remote symptoms monitoring, can improve the quality of life of patients with a diagnosis of cancer receiving systemic anticancer treatment. The main question it aims to answer is: \- Do patients with a diagnosis of cancer receiving systemic anticancer therapy and using Resilience PRO have an improved quality of life? Researchers will compare patients using Resilience PRO plus care as usual to patients receiving care as usual only. Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important symptoms, an alert is sent to the care team that can incorporate that information to timely adjust the care of the participants. Participants both in the control arm and in the intervention arm will further receive care as usual.
This description comes directly from the study's public registry record.
Resilience · +33 805 69 65 61 · support@resilience.care
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age: Adults ≥ 18 years. * Informed Consent: Patient giving signed informed consent to participate in the RC - 102 clinical study. * Diagnosis: Patients with cancer at any stage. * Systemic Treatment * Remote Monitoring Eligibility: Access to a smartphone * Language: Ability to understand and communicate in the language(s) in which the trial is conducted. Exclusion Criteria: * Age: Patients under 18 years of age. * Life Expectancy: Patients with a life expectancy of less than 6 months as estimated by the treating physician. * Concurrent remote monitoring * HSCT or CAR-T Therapy * Cognitive Impairment * Pregnancy or breastfeeding * Subject under administrative or judicial control
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Hôpital Privé de Provence | Aix-en-Provence, France | Recruiting |
| Centre Hospitalier du Pays d'Aix - Centre Hospitalier Intercommunal Aix-Pertuis | Aix-en-Provence, France | Recruiting |
| Centre Hospitalier Henri Mondor-Aurillac | Aurillac, France | Recruiting |
| Centre Hospitalier de la Côte Basque | Bayonne, France | Recruiting |
| Centre Hospitalier Universitaire de Caen Normandie | Caen, France | Recruiting |
| Centre Hospitalier Universitaire de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| Centre Hospitalier Universitaire Grenoble - Alpes | La Tronche, France | Recruiting |
| GHICL Hôpital Saint Vincent de Paul | Lille, France | Recruiting |
| Centre Hospitalier Universitaire de Lille | Lille, France | Recruiting |
| Hôpital Privé Jean Mermoz - Institut de Cancérologie | Lyon, France | Recruiting |
| AP-HM Assistance Publique - Hôpitaux de Marseille Hôpital de la Timone | Marseille, France | Recruiting |
| Centre Hospitalier Universitaire de Nantes | Nantes, France | Recruiting |
+ 24 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06867705